CD33 and acute myeloid leukemia: In addition, the immunotoxin gemtuzumab ozogamicin (a humanized mAb targeting CD33 and is approved for the treatment of CD33-positive AML) was reported to decrease MDSCs levels and reactivate T cell and CAR-T cell effects against multiple cancers in vitro.338